SLC5A2 and type 2 diabetes mellitus: The SGLT2 inhibitor CANA provided clinically meaningful body-weight reductions, and each 1% reduction in body weight was associated with a 0.62-mmHg reduction in systolic BP in patients with type 2 diabetes [37].